Synthetic Biology and the “Bioeconomy”: Feeding Fuel to the Fire of Landgrabs and
Biodiversity Loss
By Eric Hoffman and Jeff Conant,
Global Forest Coalition
| 02. 14. 2013
[For footnotes, see here]
The industrial revolution replaced wood for fossil fuels as the driver of the engine of progress, leaving living plants to take a back seat in energy production. Now, with the advent of a set of technologies known as synthetic biology, industry groups and the US Department of Energy are celebrating the advent of a new “bioeconomy” – an energy and materials economy in which products and processes previously derived from petroleum will be produced through the exploitation of biomass and biotechnology. By employing the rapidly expanding techniques of synthetic biology, the new industrialists want to turn microbes into “living chemical factories” engineered to produce substances they would not produce naturally, such as biofuels, bio-plastics, industrial chemicals and oils, and even medicines.
However, early indications show that such an approach likely harbors all of the ill-effects of the fossil fuel economy – simply swapping out black carbon for green – combined with the assault on biodiversity brought on by biotechnologies such as genetic engineering of crops. Humans have already caused a state-shift in the global ecosystem...
Related Articles
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
By Robert Resta, The DNA Exchange | 07.22.2024
Medical geneticists and genetic counselors have an often complicated and at times tense relationship with people with disabilities, their families, advocates, and scholars. Geneticists are strong advocates and supporters for all of their patients, regardless of their abilities and disabilities...
By Katherine Bourzac, Nature | 07.10.2024
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...